As analyzed by immunohistochemistry, in HCC-LM3 tumors, Dp44mT treatment exhibited the inhibition of typical EMT phenotype, including focal increment of the epithelial marker E-cadherin and concurrent loss of the mesenchymal marker vimentin and N-cadherin. This evidence concerns the gene CDH1 and hepatocellular carcinoma.